Target intelligence / Profile preview

Plasmodium falciparum liver stage antigen (multiple variants identified) (LSA-1, LSA-3, and related liver stage antigens)

Target: LSA-1, LSA-3, and related liver stage antigens
Molecular classification: Parasite protein antigen, Vaccine candidate, Exported protein (PEXEL-containing for LSA-3)[7], Parasitophorous vacuole-associated protein

Overview

Plasmodium falciparum liver stage antigens, including LSA-1 and LSA-3, are parasite proteins exclusively expressed during the pre-erythrocytic liver infection stage of malaria.[1][5] LSA-1 is a 230-kDa protein characterized by a large central repeat region flanked by conserved N- and C-terminal domains; it accumulates in the parasitophorous vacuole surrounding developing merozoites and is thought to play a critical role in parasite multiplication and merozoite release from infected hepatocytes.[1][5] LSA-3 is an exported protein containing a PEXEL motif that localizes to the parasitophorous vacuole membrane and contributes to parasite fitness during liver stage development.[7] These antigens are not traditional enzyme or receptor targets but rather **vaccine immunogens** designed to elicit protective CD4+ and CD8+ T cell responses and antibodies that prevent parasite development in the liver before blood stage infection.[3][5][6] Clinical trials and preclinical studies have demonstrated that CD4+ T cell responses against these antigens correlate with protection against reinfection, making them valuable components of multi-antigen malaria vaccine strategies.[3] Their liver stage-specific expression and lack of mammalian homologs make them attractive vaccine candidates with favorable safety profiles for malaria prevention in endemic populations.

Other names: Liver-stage antigen 1 (LSA-1)[1][5]Liver-stage antigen 3 (LSA-3)[6][7][10]LISP1 (Liver-stage infected cell protein 1)[3]PALM (related liver stage antigen)[3]ALAS (aminolevulinic acid synthase, liver stage)[3]Pre-erythrocytic stage antigensHepatocyte-expressed parasite antigens

Mechanism of action

LSA antigens contain epitopes that activate CD4+ T cells. B cell epitopes in the N- and C-terminal regions of LSA-1 generate protective antibodies. Specific immune responses to LSA proteins induce interferon-gamma and other cytokines. These responses prevent parasite development in the liver before blood stage infection occurs.

Biological functions

Liver stage development: LSA-1 accumulates within the parasitophorous vacuole and appears to play a role in liver schizogony (parasite multiplication) and merozoite formation[1][5]Host cell remodeling: LSA-3 is an exported protein involved in modifying the infected hepatocyte environment[7]Parasite-host interaction: These antigens mediate interactions between the parasite and host hepatocyteImmune response generation: LSA proteins stimulate both humoral (antibody) and cellular (T cell) immune responses[1][5]Merozoite release: LSA-1 is localized around developing merozoites and appears involved in their release from infected hepatocytes[1]

Disease associations

Malaria infection: These are exclusively expressed during the pre-erythrocytic (liver) stage of Plasmodium falciparum infection[2][5]Vaccine target: LSA antigens are being developed as components of malaria vaccines to prevent infection[5][6][10]Immune protection: CD4+ T cell responses against liver stage antigens, particularly LISP1, correlate with protection against reinfection[3]

Safety considerations

No significant safety concerns with the antigens themselves were identified in the literature. However, vaccine development considerations include:Stage-specific expression: LSA-1 is uniquely expressed in P. falciparum and not found in other Plasmodium species except P. reichenowi, limiting potential cross-reactivity concerns[1]Protein structure: LSA-1 undergoes complex post-translational modification (cross-linking by tissue transglutaminase), which must be considered in vaccine formulation[1]

Interacting drugs

Vaccine immunogens

Biomarkers

CD4+ T cell response frequency: Responding CD4+ T cells targeting LISP1 peptides can exceed 40% specificity in immunized individuals[3]Antibody titers: Humoral immune responses to LSA-1 correlate with immune activation[5]IFN-γ production: Interferon-gamma production by T cells specific to liver stage antigens measured by ELISPOT and flow cytometry[3]HLA-DRβ1*1101 binding: LSA-1 N-terminal peptides bind to this MHC allele, predicting CD4+ T cell activation[1]

Beyond the preview

Go deeper on Plasmodium falciparum liver stage antigen (multiple variants identified) (LSA-1, LSA-3, and related liver stage antigens).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasmodium falciparum liver stage antigen (multiple variants identified) (LSA-1, LSA-3, and related liver stage antigens).

Explore the full profile